Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection

Intervirology

Volumn 47, Issue 6, 2004, Pages 335-341

  Tsubota, Akihito ^a,b   Arase, Yasuji ^b   Suzuki, Yoshiyuki ^b   Suzuki, Fumitaka ^b   Hosaka, Tetsuya ^b   Akuta, Norio ^b   Someya, Takashi ^b   Kobayashi, Masahiro ^b   Saitoh, Satoshi ^b   Ikeda, Kenji ^b   Kumada, Hiromitsu ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis B; Hepatic failure; Lamivudine; Severe acute exacerbation; Severe acute exacerbation chronic hepatitis B virus infection

Indexed keywords

LAMIVUDINE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CONFIDENCE INTERVAL; DATA BASE; DISEASE COURSE; DISEASE EXACERBATION; ENDEMIC DISEASE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS INFECTION;

ACUTE DISEASE; ADULT; COHORT STUDIES; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 9144243211     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080877     Document Type: Article

References (32)

1. Maddrey WC: Hepatitis B: An important public health issue. J Med Virol 2000;61:362-366.
2. Chen CJ, Wang LY, Yu MW: Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000;15(suppl):E3-E6.
3. Takahashi Y, Shimizu M, The study group of fulminant hepatitis: Aetiology and prognosis of fulminant viral hepatitis in Japan: A multicentre study. J Gastroenterol Hepatol 1991;6:159-164.
4. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC: Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy- 3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-8499.
5. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
6. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA, Thomas HC: Lamivudine therapy for chronic hepatitis B: A six-month randomized doseranging study. Gastroenterology 1997;113:1258-1263.
7. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
8. Tsubota A, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Chayama K, Murashima N, Ikeda K, Kobayashi M, Kumada H: Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: A preliminary study. Am J Gastroenterol 2001;96:557-562.
9. Chan HL, Tsang SW, Hui Y, Leung NW, Chan FK, Sung JJ: The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat 2002;9:424-428.
10. Tsang SW, Chan HL, Leung NW, Chau TN, Lai ST, Chan FK, Sung JJ: Lamivudine treatment for fulminant hepatic failure due to acute exacerbation on chronic hepatitis B infection. Aliment Pharmacol Ther 2001;15:1737-1744.
11. Chien RN, Lin CH, Liaw YF: The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 2003;38:322-327.
12. Lok AS, Heathcote EJ, Hoofnagle JH: Management of Hepatitis B: 2000 - Summary of a Workshop. Gastroenterology 2001;120:1828-1853.
13. Lok ASF, McMahon BJ: Chronic hepatitis B. Hepatology 2001;34:1225-1241.
14. Trey C, Davidson LS: The management of fulminant hepatic failure; in Popper H, Schaffner F (eds): Progress in Liver Disease. New York, Grune & Stratton, 1970, vol 3, pp 282-298.
15. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K: Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994;19:1088-1094.
16. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, Mayumi M: Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999;80:97-112.
17. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H, et al: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-1716.
18. Yuen MF, Lai CL: Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000;15(suppl):E20-E24.
19. Kidd-Ljunggren K, Miyakawa Y, Kidd AH: Genetic variability in hepatitis B viruses. J Gen Virol 2002;83:1267-1280.
20. Kao JH, Chen PJ, Lai MY, Chen DS: Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. Hepatology 2001;34:817-823.
21. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Someya T, Matsuda M, Sato J, Kumada H: Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol 2002;37:35-39.
22. Chan HL, Tsang SW, Wong ML, Tse CH, Leung NW, Chan FK, Sung JJ: Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. Am J Gastroenterol 2002;97:2629-2633.
23. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Ueda R, Miyakawa Y, Mizokami M: Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002;76:5985-5992.
24. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K: Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-748.
25. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
26. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN, on behalf of the Asia Hepatitis Lamivudine Study Group: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-1532.
27. Chien RN, Liaw YF, Atkins M: Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770-774.
28. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180.
29. Chang TT, Lai CL, Liaw YF: Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for years (abstract). Antivir Ther 2000;5(suppl 1):44A.
30. Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM: Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000;32:604-609.
31. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS: Lack of effect of antiviral therapy in non-dividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997;71:9392-9399.
32. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH, et al: Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-834.